Topical ruxolitinib cream for pyoderma gangrenosum ulcers
Part of Injuries & trauma, Skin clinical trials.
This study tests a cream called ruxolitinib to treat pyoderma gangrenosum, a painful skin condition that causes deep ulcers. The cream is applied directly to the ulcer and may help it heal without the side effects of pills or injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 99 years old.
- You must have at least one pyoderma gangrenosum ulcer that is no larger than 10 cm².
- You must be willing to apply the study cream and follow the study procedures.
- You must be able to travel to OHSU for visits or have internet and a webcam for remote visits.
- You must not have taken certain immunosuppressant drugs (like azathioprine or cyclosporine) or other JAK inhibitors (like tofacitinib or upadacitinib).
- You must not have had cancer (except certain skin cancers) in the past 5 years, or have active infections like HIV, hepatitis B, or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called bimekizumab to see if it helps people with pyoderma gangrenosum, a painful skin condition that causes deep ulcers. If you qualify, you'll receive the treatment and be monitored for about a year.
This study tests an experimental drug called SHR-1139 to see if it can help heal skin ulcers caused by pyoderma gangrenosum. If you qualify, you would receive the study drug and be monitored for safety and effectiveness.
This study tests an investigational drug called SHR-1139 for adult patients with ulcerative pyoderma gangrenosum (a type of painful skin ulcer). The goal is to see if the drug is safe and helps heal the ulcers.
This trial tests whether the drug spesolimab can help people with a skin condition called pyoderma gangrenosum, which causes painful ulcers. It's for adults who have at least one active ulcer that's at least 2 inches across and needs treatment.
This study tests a cream called ruxolitinib on the skin rash caused by graft-versus-host disease (GVHD) after a bone marrow or stem cell transplant. The goal is to see if the cream safely reduces the rash without needing stronger medicines by mouth.
This trial tests a cream called ruxolitinib for people with dermatomyositis whose skin symptoms haven't improved with standard treatments. It aims to see if this cream can reduce rash and activity when added to your current medications.
Hear when a new Pyoderma Gangrenosum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.